Predictive Toxicology, Philadelphia, PA, USA
Event Sep 08
Strategies to Reduce Late Stage Drug Failures and Address Bottlenecks of In-vitro and In-vivo Toximetabolism Using High-Throughput Methods. $70 million of the total R&D costs per drug are spent on ADME/Tox failures! Due to the high cost of late-stage failure and the impact of adverse drug reactions, it is critical to eliminate toxic compounds as early as possible in the drug development process. This comprehensive event featuring industry, academic and agency case studies offers strategies to reduce late stage drug failures and address bottlenecks of in-vitro and in-vivo toximetabolism using high-throughput methods.